Forest's COPD Drug May Have Added Heart Risks: FDA
A U.S. Food and Drug Administration staff report Tuesday noted the effectiveness of a proposed Forest Laboratories Inc. chronic obstructive pulmonary disease drug, but brought up concerns that the drug could...To view the full article, register now.
Already a subscriber? Click here to view full article